These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 17579393)
1. A theoretical study on the hydrolysis process of the antimetastatic ruthenium(III) complex NAMI-A. Chen J; Chen L; Liao S; Zheng K; Ji L J Phys Chem B; 2007 Jul; 111(27):7862-9. PubMed ID: 17579393 [TBL] [Abstract][Full Text] [Related]
2. The hydrolysis process of the anticancer complex [ImH][trans-RuCl4(Im)2]: a theoretical study. Chen J; Chen L; Liao S; Zheng K; Ji L Dalton Trans; 2007 Aug; (32):3507-15. PubMed ID: 17680040 [TBL] [Abstract][Full Text] [Related]
3. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations. Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562 [TBL] [Abstract][Full Text] [Related]
4. Aquation of the ruthenium-based anticancer drug NAMI-A: a density functional study. Besker N; Coletti C; Marrone A; Re N J Phys Chem B; 2008 Apr; 112(13):3871-5. PubMed ID: 18331025 [TBL] [Abstract][Full Text] [Related]
5. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A. Ravera M; Baracco S; Cassino C; Zanello P; Osella D Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891 [TBL] [Abstract][Full Text] [Related]
7. Quantum Chemical Studies on Detail Mechanism of Nitrosylation of NAMI-A-HSA Adduct. Das D; Mondal P J Phys Chem B; 2015 Aug; 119(33):10456-65. PubMed ID: 26151453 [TBL] [Abstract][Full Text] [Related]
8. Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form. Mazuryk O; Kurpiewska K; Lewiński K; Stochel G; Brindell M J Inorg Biochem; 2012 Nov; 116():11-8. PubMed ID: 23010324 [TBL] [Abstract][Full Text] [Related]
9. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin. Webb MI; Walsby CJ Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063 [TBL] [Abstract][Full Text] [Related]
11. A theoretical study on the hydrolysis process of two Keppler-type antitumor complexes [TzH][trans-RuCl4(Tz)2] and [2-NH2TzH][trans-RuCl4(2-NH2Tz)2]. Chen JC; Chen LM; Liao SY; Zheng KC; Ji LN Phys Chem Chem Phys; 2009 May; 11(18):3401-10. PubMed ID: 19421541 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A. Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867 [TBL] [Abstract][Full Text] [Related]
13. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322 [TBL] [Abstract][Full Text] [Related]
14. The second-generation anticancer drug Nedaplatin: a theoretical investigation on the hydrolysis mechanism. Alberto ME; Lucas MF; Pavelka M; Russo N J Phys Chem B; 2009 Oct; 113(43):14473-9. PubMed ID: 19778071 [TBL] [Abstract][Full Text] [Related]
15. Neutral and acidic hydrolysis reactions of the third generation anticancer drug oxaliplatin. Lucas MF; Pavelka M; Alberto ME; Russo N J Phys Chem B; 2009 Jan; 113(3):831-8. PubMed ID: 19143575 [TBL] [Abstract][Full Text] [Related]
16. Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. Ravera M; Baracco S; Cassino C; Colangelo D; Bagni G; Sava G; Osella D J Inorg Biochem; 2004 Jun; 98(6):984-90. PubMed ID: 15149805 [TBL] [Abstract][Full Text] [Related]
17. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole. Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346 [TBL] [Abstract][Full Text] [Related]
18. The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin. Brindell M; Stawoska I; Supel J; Skoczowski A; Stochel G; van Eldik R J Biol Inorg Chem; 2008 Aug; 13(6):909-18. PubMed ID: 18438690 [TBL] [Abstract][Full Text] [Related]
19. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro. Hostetter AA; Miranda ML; DeRose VJ; McFarlane Holman KL J Biol Inorg Chem; 2011 Dec; 16(8):1177-85. PubMed ID: 21739255 [TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity. Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]